Regeneus prepares for global growth with appointment of life sciences industry leaders

Friday, 10 May 2019

ASX listed regenerative medicine company Regeneus (ASX: RGS) has today announced the appointments of John Chiplin, PhD and Alan W. Dunton, M.D. to its board of directors.

Joining Regeneus as Non-Executive Directors, both Chiplin and Dunton bring significant experience in leading and growing large-scale life sciences and biotechnology companies internationally.

The appointments come at a time when Regeneus is seeking to roll out its global growth strategy targeting the global pain market.

The neuropathic pain market alone is estimated to be worth US$69 billion and forecast to reach US$79 Billion by 2024.

The addition of Chiplin and Dunton to the board and their proven successes in sourcing global capital and global drug commercialisation will be key in supporting Regeneus as it enters this next phase of growth.

Regeneus CEO Leo Lee commented on the significance of the two Non-Executive Directors and the role the appointees will play in the company’s growth strategy.

“I am very pleased to welcome both Alan and John to the Board to support us through the Company’s next phase of growth and commercialisation.”

“Their appointments bring a new mix of invaluable skills to support us through our next phase of growth, as we focus on commercialising our technology to address the huge and growing global pain market.”

“With the deep experience John brings in raising capital internationally and Alan’s extensive experience in commercialising drugs on a global scale, I am confident of the significant value that will result from their strategic guidance and international connections.”

Chiplin, a veteran in the life science and technology industries, has served as CEO at three leading publicly-listed software, biotechnology and cancer immunotherapy companies.

Currently the Managing Director of Newstar Ventures, Chiplin also holds positions on the boards of Adalta (ASX:1AD), Batu Biologics, Cynata Therapeutics (ASX:CYP), Scancell Holdings (LSE: SCLP, Chairman) and ScienceMedia.

Chiplin adds to the Regeneus board a proven track record in sourcing global capital, aligning well with the company’s expanding global growth strategy.

As Executive Chairman at Scancell, Chiplin successfully led a GBP 20 million fundraise from institutional investors.

Chiplin’s expertise are further showcased from his time as Executive Director at Benitec Inc, where he led the company’s IPO on the NASDAQ and a US$46 million raising with US-based institutional investors.

Complementing Chiplin’s vast industry experience is the appointment of Dunton, a senior figure in the commercial biotech and pharmaceutical industries.

Boasting close to three decades of senior leadership experience in the sector, Dunton is a specialist in direct stem cell research and pain management, and is a veteran of the commercial drug and pain management market.

Dunton’s experience spans leadership roles for large pharmaceutical research and development organisations to private biotechnology companies focused on prescriptive treatment and over-the-counter drug development on a global and local scale.

Dunton has served as a director of 18 companies and is the founder and principal of Danerius LLC, a consultancy that provides specialised advisory services to pharmaceutical and biotechnology organisations both in the private and public sectors.

Over the last few years, Dunton has also served as an independent board director for a variety of publicly-listed biopharmaceutical and drug development companies such as Oragenics (NYSE:OGEN), Palatin Technologies (NYSE:PTN) and Cytogel Pharma.

The appointments of Chiplin and Dunton to the Regeneus board will provide invaluable support the company in the further development and commercialisation of its Progenza and Sygenus platforms.

Coinciding with the appointment of Chiplin and Dunton, Regeneus announced Mr Roger Aston and Mr John Martin have stepped down from their roles as Non-Executive Chairman and Non-Executive Director respectively.

Click here for the original article published in Star Investing